Discover undervalued stocks with Eulerpool.

Subscribe for $2

Compass Pathways Stock CMPS

Price

0
Today +/-
-0
Today %
-0 %

Compass Pathways stock price

Loading chart...
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Compass Pathways stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Compass Pathways stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Compass Pathways stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Compass Pathways's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Compass Pathways Stock Price History

DateCompass Pathways Price
10/18/20250 undefined
10/17/20256.55 undefined
10/17/20256.55 undefined
10/16/20256.45 undefined
10/15/20256.88 undefined
10/14/20256.72 undefined
10/13/20256.40 undefined
10/10/20256.02 undefined
10/10/20256.02 undefined
10/9/20256.58 undefined
10/8/20256.52 undefined
10/7/20256.37 undefined
10/6/20256.22 undefined
10/3/20256.45 undefined
10/3/20256.31 undefined
10/2/20255.93 undefined
10/1/20255.65 undefined
9/29/20255.73 undefined
9/28/20255.87 undefined
9/25/20255.80 undefined
9/24/20255.66 undefined
9/24/20255.57 undefined
9/24/20255.57 undefined
9/23/20255.07 undefined
9/22/20255.12 undefined
9/19/20254.94 undefined

Compass Pathways Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Compass Pathways, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Compass Pathways from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Compass Pathways’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Compass Pathways. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Compass Pathways’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Compass Pathways’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Compass Pathways’s growth potential.

Compass Pathways Revenue, EBIT and net profit per share

DateCompass Pathways RevenueCompass Pathways EBITCompass Pathways Net Income
2030e770.28 M undefined1.53 B undefined-33.27 M undefined
2029e399.76 M undefined-42.86 M undefined-149.72 M undefined
2028e159.6 M undefined-179.93 M undefined-144.83 M undefined
2027e10.64 M undefined-215.91 M undefined-141.48 M undefined
2026e0 undefined-195 M undefined-149.14 M undefined
2025e0 undefined-182.68 M undefined-146.7 M undefined
20240 undefined-178.21 M undefined-155.12 M undefined
20230 undefined-127.12 M undefined-118.46 M undefined
20220 undefined-99 M undefined-91.51 M undefined
20210 undefined-74.57 M undefined-71.74 M undefined
20200 undefined-44.56 M undefined-60.33 M undefined
20190 undefined-21.18 M undefined-19.61 M undefined
20180 undefined-12.5 M undefined-13.22 M undefined

Compass Pathways Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M)
NET INCOME (M)
NET INCOME GROWTH (%)
SHARES (M)
DOCUMENTS
20182019202020212022202320242025e2026e2027e2028e2029e2030e
00000000010159399770
----------1,490.00150.9492.98
-------------
0000000000000
-13-19-60-71-91-118-155-146-149-141-144-149-33
-46.15215.7918.3328.1729.6731.36-5.812.05-5.372.133.47-77.85
33.4533.4535.934042.4451.0367.48000000
- - - - - - - - - - - - -
Details

Keystats

ⓘ

Revenue and Growth

The Compass Pathways Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Compass Pathways is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (M)
RECEIVABLES (M)
OTHER REC. (M)
INVENTORIES (M)
OTHER CURRENT LIAB. (M)
CURRENT ASSETS (M)
TANGIBLE ASSETS (M)
LONG-T. INVEST. (k)
LONG-T. REC. (M)
INTANGIBLE ASSETS (M)
GOODWILL (M)
OTHER NON-CURRENT ASSETS (M)
NON-CURRENT ASSETS (M)
TOTAL ASSETS (M)
LIABILITIES
COMMON STOCK (M)
ADDITIONAL PAID-IN CAPITAL (M)
RETAINED EARNINGS (M)
OTHER EQUITY (M)
UNREAL. GAINS/LOSSES (M)
EQUITY (M)
LIABILITIES (M)
PROVISIONS (M)
OTHER SHORT-TERM LIAB. (M)
SHORT-TERM DEBTS (M)
LONG-TERM DEBT PORTION (M)
SHORT-TERM REC. (M)
LONG-T. LIAB. (M)
DEFERRED TAXES (M)
OTHER LIAB. (M)
LONG-T. LIABILITIES (M)
DEBT (M)
TOTAL CAPITAL (M)
2018201920202021202220232024
             
22.925190.3273.2143.2220.2165.08
0000000
0000000
0000000
1.226.310.832.812.1714.39
24.127196.6284176232.37179.47
0.10.20.24.12.64.732.2
00500500500469469
0000000
0000000
0000000
000.312.69.499.71
0.10.215.65.714.6912.38
24.227.2197.6289.6181.7247.06191.85
             
39390.40.50.50.640.7
3.97.1279.5444.8458.8621.65704.92
-18-37.6-97.9-169.6-261.1-379.61-534.73
-0.4-0.114.68.8-16.9-16.93-16.19
0000000
24.58.4196.6284.5181.3225.74154.7
0.71.32.72.64.85.8912.28
1.21.43.512.310.212.6914.9
00.10.70.30.71.031.33
021.100000
0000005.51
1.923.96.915.215.719.634.02
0000028.7624.65
0000000
0001.40.41.880.3
0001.40.430.6424.96
1.923.96.916.616.150.2458.97
26.432.3203.5301.1197.4275.99213.67
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Compass Pathways provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Compass Pathways's financial health and stability.

Assets

Compass Pathways's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Compass Pathways must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Compass Pathways after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Compass Pathways's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)
DEPRECIATION (M)
DEFERRED TAXES (M)
CHANGES IN WORKING CAPITAL (M)
NON-CASH ITEM (M)
PAID INTEREST (k)
PAID TAXES (M)
NET CASH FLOW FROM OPERATING ACTIVITIES (M)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (M)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (M)
NET CHANGE IN EQUITY (M)
CASH FLOW FROM FINANCING ACTIVITIES (M)
CASH FLOW FROM OTHER FINANCING ACTIVITIES ()
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (M)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
201820192020202120222023
-13-19-60-71-91-118
000000
0000-1-1
0-20-5-285
5737192934
000001,000
000000
-9-17-41-67-105-97
000000
000000
000000
000000
81800029
2401941561145
32181941561173
------1.00
000000
21216582-12977
-9.93-17.98-41.51-68.08-106.05-97.44
000000

Compass Pathways stock margins

The Compass Pathways margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Compass Pathways. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Compass Pathways.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Compass Pathways's sales revenue. A higher gross margin percentage indicates that the Compass Pathways retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Compass Pathways's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Compass Pathways's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Compass Pathways's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Compass Pathways. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Compass Pathways's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Compass Pathways Margin History

Compass Pathways Gross marginCompass Pathways Profit marginCompass Pathways EBIT marginCompass Pathways Profit margin
2030e0 %197.98 %-4.32 %
2029e0 %-10.72 %-37.45 %
2028e0 %-112.74 %-90.75 %
2027e0 %-2,028.87 %-1,329.41 %
2026e0 %0 %0 %
2025e0 %0 %0 %
20240 %0 %0 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %

Compass Pathways Stock Sales Revenue, EBIT, Earnings per Share

The Compass Pathways earnings per share therefore indicates how much revenue Compass Pathways has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Compass Pathways earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Compass Pathways's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Compass Pathways’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Compass Pathways's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Compass Pathways Revenue, EBIT and net profit per share

DateCompass Pathways Sales per ShareCompass Pathways EBIT per shareCompass Pathways Earnings per Share
2030e8.03 undefined22.6 undefined-0.35 undefined
2029e4.17 undefined-0.64 undefined-1.56 undefined
2028e1.66 undefined-2.67 undefined-1.51 undefined
2027e0.11 undefined-3.2 undefined-1.47 undefined
2026e0 undefined-2.89 undefined-1.55 undefined
2025e0 undefined-2.71 undefined-1.53 undefined
20240 undefined-2.64 undefined-2.3 undefined
20230 undefined-2.49 undefined-2.32 undefined
20220 undefined-2.33 undefined-2.16 undefined
20210 undefined-1.86 undefined-1.79 undefined
20200 undefined-1.24 undefined-1.68 undefined
20190 undefined-0.63 undefined-0.59 undefined
20180 undefined-0.37 undefined-0.4 undefined

Compass Pathways business model

Compass Pathways PLC is a leading company specializing in the development of groundbreaking therapies for the treatment of mental illnesses. The company was founded in 2016 and is headquartered in London. Its goal is to revolutionize the treatment of depression and other mental illnesses. The business model of Compass Pathways is based on researching psychedelics as a potential treatment for patients suffering from severe depression and anxiety disorders. The company uses innovative approaches to precisely study the effects of psychedelics on the human brain and develop new therapy concepts and products from that. An important area of Compass Pathways is clinical research. The company collaborates closely with leading research institutions to understand the impacts of psychedelics on the human brain. The research results are then used to develop innovative methods for therapeutic use of psychedelics. Another important area of Compass Pathways is the development of therapeutic products. The company has developed a patented process for producing psilocybin, a substance found in hallucinogenic mushrooms. This process achieves a very high purity of the substance, enabling precise dosing and better control of its effects. The flagship product of Compass Pathways is COMP360, a medication based on psilocybin that is being developed for the treatment of depression. The medication is currently in clinical Phase 2 trials, showing promising results. If COMP360 receives approval, it has the potential to drastically change the way we treat depression. Compass Pathways is also active in other areas. The company conducts a range of research projects related to various psychedelic substances, including LSD and other hallucinogens. Another important area of Compass Pathways is training therapists and other professionals in the use of psychedelic substances. The company offers relevant courses to promote understanding of the therapeutic use of psychedelics and enable their safe and effective application for patient treatment. Overall, Compass Pathways is a company focused on the development of groundbreaking therapies for mental illnesses. Through combining cutting-edge research, innovative products, and professional education, the company has the potential to revolutionize the way we treat mental illnesses. Compass Pathways is one of the most popular companies on Eulerpool.com.

Compass Pathways SWOT Analysis

Strengths

Compass Pathways PLC has several strengths that contribute to its success in the market. Firstly, the company is backed by significant funding, allowing it to invest in research and development and establish itself as a key player in the emerging field of mental health treatment. Secondly, Compass Pathways has a strong network of partnerships and collaborations with leading academic institutions and healthcare organizations, enabling access to valuable expertise and resources. Lastly, the company has patented technologies and intellectual property, giving it a competitive edge in the development and commercialization of innovative therapies.

Weaknesses

Despite its strengths, Compass Pathways PLC also faces certain weaknesses that could potentially hinder its growth. One of the major challenges is the high cost associated with the research and development of novel treatments, which may impact the company's profitability and ability to bring products to market in a timely manner. Additionally, as a relatively young company, Compass Pathways has limited brand recognition and market presence, which could pose obstacles in gaining traction and competing with established players in the industry.

Opportunities

The market offers numerous opportunities for Compass Pathways PLC to capitalize on. The growing awareness and acceptance of psychedelic-assisted therapies present a favorable environment for the company to position itself as a leader in this therapeutic field. Furthermore, the increasing prevalence of mental health disorders globally creates a significant demand for effective treatments, offering a vast market for Compass Pathways' innovative solutions. Moreover, strategic partnerships and collaborations with pharmaceutical companies and healthcare providers can help accelerate the development, commercialization, and distribution of the company's therapies.

Threats

Compass Pathways PLC faces several threats that could impact its business operations and market position. One prominent threat is the regulatory landscape and the potential for stringent regulations surrounding psychedelic-assisted therapies, which could limit market access and increase compliance costs. Additionally, competition within the mental health treatment industry is intensifying, and new entrants or existing players developing alternative therapies could erode Compass Pathways' market share. Moreover, there is a risk of unforeseen adverse events or negative public perception related to psychedelic treatments, which may lead to reputational damage and skepticism among key stakeholders.

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Compass Pathways Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Compass Pathways historical P/E ratio, EBIT multiple, and P/S ratio

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Compass Pathways shares outstanding

The number of shares was Compass Pathways in 2024 — This indicates how many shares 67.483 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Compass Pathways earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Compass Pathways's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Compass Pathways’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Compass Pathways's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Compass Pathways.

Compass Pathways latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2025-0.44 -0.41  (6.09 %)2025 Q2
3/31/2025-0.48 -0.38  (20.35 %)2025 Q1
12/31/2024-0.64 -0.63  (2.27 %)2024 Q4
9/30/2024-0.58 -0.56  (3.86 %)2024 Q3
6/30/2024-0.53 -0.56  (-4.83 %)2024 Q2
3/31/2024-0.5 -0.55  (-10.95 %)2024 Q1
12/31/2023-0.34 -0.53  (-57.46 %)2023 Q4
9/30/2023-0.44 -0.67  (-51.24 %)2023 Q3
6/30/2023-0.71 -0.62  (12.42 %)2023 Q2
3/31/2023-0.7 -0.57  (18.41 %)2023 Q1
1
2

Compass Pathways shareholders

%
Name
Stocks
Change
Date
9.20472 % Deep Track Capital LP8,831,007-28,6416/30/2025
8.56987 % RTW Investments L.P.8,221,9292,683,7616/30/2025
7.19801 % Atai Life Sciences AG6,905,77403/5/2025
4.35682 % Nantahala Capital Management, LLC4,179,9301,350,6986/30/2025
3.50467 % Vivo Capital, LLC3,362,38506/30/2025
2.13708 % Goldsmith (George Jay)2,050,319-129,3343/31/2025
2.11311 % Malievskaia (Ekaterina)2,027,318-149,3763/31/2025
1.85712 % GMT Capital Corp.1,781,71806/30/2025
1.85455 % PFM Health Sciences, LP1,779,2591,327,9926/30/2025
1.83025 % Woodline Partners LP1,755,9381,0826/30/2025
1
2
3
4
5
...
10

Compass Pathways Executives and Management Board

Mr. Kabir Nath

(60)
Compass Pathways Chief Executive Officer, Executive Director (since 2022)
Compensation 4.34 M

Ms. Teri Loxam

(53)
Compass Pathways Chief Financial Officer
Compensation 2.35 M

Dr. Guy Goodwin

(77)
Compass Pathways Chief Medical Officer
Compensation 1.48 M

Mr. David Norton

(73)
Compass Pathways Independent Director
Compensation 411,562

Mr. Gino Santini

(68)
Compass Pathways Non-Executive Independent Chairman of the Board
Compensation 410,440
1
2
3

Most common questions regarding Compass Pathways

What values and corporate philosophy does Compass Pathways represent?

Compass Pathways PLC represents a strong commitment to advancing mental health treatment. The company's corporate philosophy revolves around using innovation and rigorous scientific research to address the unmet needs in mental health care. Compass Pathways PLC places a high value on patients' well-being and aims to revolutionize the treatment of challenging mental health conditions like treatment-resistant depression through their breakthrough therapy, psilocybin. By emphasizing safety, efficacy, and patient-centric care, Compass Pathways PLC aspires to empower individuals suffering from mental health disorders and improve their quality of life.

In which countries and regions is Compass Pathways primarily present?

Compass Pathways PLC, a leading mental healthcare company, is primarily present in the United States, United Kingdom, and Europe. With a global presence and a mission to develop innovative therapies, Compass Pathways PLC has established itself as a prominent player in the mental health treatment market. The company is specifically focused on developing psilocybin therapy, a potential breakthrough treatment for depression and other mental health disorders. With its strategic presence in key regions, Compass Pathways PLC aims to shape the future of mental healthcare worldwide.

What significant milestones has the company Compass Pathways achieved?

Compass Pathways PLC, a renowned mental healthcare company, has achieved several significant milestones. Firstly, the company successfully obtained FDA breakthrough therapy designation for their psilocybin therapy, affirming its potential to address treatment-resistant depression. Secondly, they initiated the ground-breaking clinical trial, COMPASS Pathways, investigating the efficacy of psilocybin-assisted therapy for depression. Moreover, Compass Pathways PLC received a USD 24.4 million grant from the European Union's Horizon 2020 program, further supporting their research efforts. Additionally, the company went public on the NASDAQ stock exchange, symbol CMPS, raising substantial capital to propel their pioneering work. These achievements highlight Compass Pathways PLC's commitment to advancing mental health treatments and their growing prominence in the field.

What is the history and background of the company Compass Pathways?

Compass Pathways PLC is a renowned mental healthcare company specializing in the research and development of psychedelic therapies. Founded in 2016, the company aims to address the significant unmet need for effective, innovative treatments for mental health conditions such as depression. With a focus on psilocybin therapy, Compass Pathways PLC actively conducts clinical trials and collaborates with world-leading research institutions to advance psychedelic-assisted therapy. By leveraging their expertise and strategic partnerships, Compass Pathways PLC strives to revolutionize mental health care and deliver transformative solutions to patients worldwide.

Who are the main competitors of Compass Pathways in the market?

The main competitors of Compass Pathways PLC in the market include companies such as MindMed Inc., Cybin Inc., and Atai Life Sciences AG.

In which industries is Compass Pathways primarily active?

Compass Pathways PLC primarily operates in the pharmaceutical and healthcare industry. As a leading mental health care company, Compass Pathways is dedicated to developing innovative therapies and advancing treatment options for patients with mental health disorders. With its focus on psilocybin therapy, the company aims to address the significant unmet needs in mental health through research, development, and collaboration with healthcare professionals. Compass Pathways PLC is committed to improving patient outcomes and transforming mental healthcare by providing effective and safe solutions for individuals living with mental health conditions.

What is the business model of Compass Pathways?

The business model of Compass Pathways PLC focuses on the development and commercialization of innovative therapies for mental health. As a leading mental health care company, Compass Pathways PLC is dedicated to improving the lives of patients suffering from treatment-resistant depression. It utilizes a patient-centered approach, conducting clinical trials to assess the efficacy and safety of its investigational treatment, psilocybin therapy. By partnering with healthcare providers, researchers, and regulatory bodies, Compass Pathways PLC aims to bring transformative mental health treatments to patients worldwide. With a strong commitment to scientific research and innovation, Compass Pathways PLC strives to address the significant unmet needs in mental health care.

What is the P/E ratio of Compass Pathways 2025?

The P/E ratio cannot be calculated for Compass Pathways at the moment.

What is the P/S ratio of Compass Pathways 2025?

The P/S cannot be calculated for Compass Pathways currently.

What is the Quality Investing of Compass Pathways?

The Quality Investing for Compass Pathways is 2/10.

What is the revenue of Compass Pathways 2025?

The revenue cannot currently be calculated for Compass Pathways.

How high is the profit of Compass Pathways 2025?

The expected Compass Pathways profit is -146.7 M USD.

What is the business model of Compass Pathways

Compass Pathways PLC is a company specializing in the development of therapeutic psychedelic products. The English company was founded in 2016 and is headquartered in London. The business model of Compass Pathways PLC involves the research and development of psychoactive substances that are intended to be used in the treatment of mental illnesses. The company focuses particularly on the development of psilocybin, a compound found in mushrooms that affects the central nervous system and is known to induce hallucinations and altered perceptions. Compass Pathways is currently active in two different areas: research and clinical development. In research, the company is working on identifying new compounds and developing new methods of administering them. The key areas of focus are effectiveness, safety, and tolerability. In the context of clinical development, Compass Pathways is engaged in testing the effectiveness and tolerability of its products in clinical trials in order to obtain market approval. One of Compass Pathways' main products is psilocybin, which is administered in the form of capsules. These are intended to be used particularly in the treatment of depression and anxiety disorders. The aim is to enable patients to have a new experience of themselves and their environment in order to establish long-term changes in thinking and behavior patterns. The company collaborates closely with various research institutions and partners to advance psychedelic research and increase acceptance of these therapeutic options. Compass Pathways is also already cooperating with online therapy providers to enable a wider use of therapy products. As a business model, Compass Pathways aims to develop innovative and effective therapeutic options to improve the quality of life for patients with mental illnesses. The company works closely with various stakeholders in the healthcare sector and emphasizes networking to increase the likelihood of success. Overall, Compass Pathways' business model is characterized by a high degree of innovation and a special focus on the needs of patients. The focus on psychedelic substances and their therapeutic use makes the company a pioneer in this novel program area.

What is the Compass Pathways dividend?

Compass Pathways pays a dividend of 0 USD distributed over payouts per year.

How often does Compass Pathways pay dividends?

The dividend cannot currently be calculated for Compass Pathways or the company does not pay out a dividend.

What is the Compass Pathways ISIN?

The ISIN of Compass Pathways is US20451W1018.

What is the Compass Pathways WKN?

The WKN of Compass Pathways is A2QCDR.

What is the Compass Pathways ticker?

The ticker of Compass Pathways is CMPS.

How much dividend does Compass Pathways pay?

Over the past 12 months, Compass Pathways paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Compass Pathways is expected to pay a dividend of 0 USD.

What is the dividend yield of Compass Pathways?

The current dividend yield of Compass Pathways is .

When does Compass Pathways pay dividends?

Compass Pathways pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Compass Pathways?

Compass Pathways paid dividends every year for the past 0 years.

What is the dividend of Compass Pathways?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Compass Pathways located?

Compass Pathways is assigned to the 'Health' sector.

Wann musste ich die Aktien von Compass Pathways kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Compass Pathways from 10/19/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/19/2025.

When did Compass Pathways pay the last dividend?

The last dividend was paid out on 10/19/2025.

What was the dividend of Compass Pathways in the year 2024?

In the year 2024, Compass Pathways distributed 0 USD as dividends.

In which currency does Compass Pathways pay out the dividend?

The dividends of Compass Pathways are distributed in USD.

All fundamentals about Compass Pathways

Our stock analysis for Compass Pathways Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Compass Pathways Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.